Bactiguard®

DNB Carnegie Small Cap Day

1 September 2025

Christine Lind, CEO

Setting the standard in infection prevention

Unmet need

Healthcare-associated infections and chronic wounds create a multi-billion cost burden

Validated technology

Products on market with global MedTech partners, supported by clinical evidence

Scalable platform

Leverageable across multiple therapeutic areas, using a licensing model

Growth drivers

EBITDA-positive with opportunities for growth in both licensing and Wound Management

High unmet medical need for infection solutions

Focus Therapeutic Areas

	Orthopedics [1-3]	Cardiology [4,5]	Neurology [6,7]	Urology [8]	Vascular access [9]
Application areas (examples)	*Hip & Knee Implants* *Spinal discs / Fusion cages* *Trauma Implants & hardware*	*Ventricular Assisted Device* *Pacemaker*	*Deep Brain Stimulator* *Vagus Nerve Stimulator* *Peripheral Nerve Stimulator*	*Foley Catheter*	*Central Venous Catheter* *Peripherally Inserted Central Catheter* *Midline Catheter*
Indicative infection rates	Primary **1-5%** Revisions **8-22%** Fracture related **5-40%**	CIED **1-7%** Structural heart **19-39%**	Modulators: **1-15%** Shunts: **5-13%**	CAUTI **9-21%** (>2 days)	CLABSI **2-10%** (>2 days)
Indicative mortality rates	**3-11%**	CIED **3-5%** Structural heart **5-10%**	**10-12%***	**1-4%**	**12-31%**
Addressable market	USD **39bn**	USD **10bn**	USD **9bn**	USD **5bn**	USD **11bn**

1. Masters et al. (2013); Acuña et al. (2021) 2. Gold et al. (2019); Patel et al. (2023) 3. Norris et al. (2019); Li et al. (2024) 4. Greenspon et al. (2011); Wilkoff et al. (2020); Solail Henrikson et al. (2011) 5. Mehra, Goldstein et al. (2022); Tong et al. (2015); Topkara et al. (2010)
6. Bendel et al. (2017); Ishizuka et al. (2007); Oh et al. (2002); Hasegawa et al. (2021) 7. Sagun Tuli et al. (2004) 8. CDC and Lo et al. 2014 9. Rosenthal et al. (2023); Alshahrani et al. (2023)

Advanced technology to prevent medical device related infections

Reduces microbial adhesion and biofilm formation

- **Ultra-thin noble metal coating**

- In contact with fluids, the noble metals create a **galvanic effect** due to their varying electro potentials

20+
materials coated

250M+
devices coated

## 100,000+
trial participants

70%
infection reduction

ZERO
adverse events
related to the coating

Palladium (Pd)

Silver (Ag)

Gold (Au)

Pd Ag Au Pd Ag Au Pd Ag Au

Au Pd Ag Au Pd Ag Au Pd

Uncoated surface

Coated surface

Validated by global MedTech partners

BD (Becton, Dickinson and Company)

One of the **largest global MedTech companies** in the world

Bactiguard engages with BD across the entire value chain, from technology through go-to-market strategies

At a glance

- Revenues: **Q2 2025** 19.2 MSEK. **2024** 124.7 MSEK
- Partnership since 1990 – 245M coated Foley catheters sold
- Exclusive global license for coated Foley catheters (ex China)

Z ZIMMER BIOMET

A **global leader** in orthopedics – comprehensive portfolio designed to maximize mobility and improve health

ZNN Bactiguard trauma implant on market under Zimmer Biomet's Infection prevention banner

At a glance

- Revenues: **Q2 2025** 14.2 MSEK. **2024** 27.7 MSEK
- Partnership since 2019
- Agreement covers trauma implant segment

Advancing the partnership pipeline

Exclusivity partnerships and **License partnerships** announced with partner name

|	Material transfer agreement	Application development partnership	Exclusivity partnership	License partnership
Orthopedics				ZIMMER BIOMET
Cardiology	✓			
Neurology				
Urology				BD wellead
Vascular access	✓			
Other	✓			

Wound Management portfolio

Preventing infections through effective, biocompatible solutions to improve wound healing

- **Hydrocyn aqua**, an innovative wound care product enabling wound healing and preventing infection

- Effective against bacteria, fungi and spores. Non-toxic, non-stinging, no adverse events in clinical studies

- Offering also includes speciality **surgical sutures,** including for cardiovascular and eye operations

At a glance

HYDROCYN®
aqua

- **Revenues:** Q2 2025 13.8 MSEK. 2024 60.9 MSEK
- **Acquired in 2020**

Pathogens attack · HOCl kills pathogen · HOCl generation · Phagosome · Pathogen destroyed · Neutrophil Cell

Total revenue driven by License partners and Wound Management growth

Revenue development

MSEK — Other revenues, BIP portfolio, Wound Management portfolio, Total license revenue

Second quarter (Apr-Jun)
- 2024: 60,9 (37,8 / 14,7 / 4,8 / 3,5)
- 2025: 52,1 (34,1 / 13,8 / 0,3 / 3,9)
- -14,4%

Year to date (Jan-Jun)
- 2024: 119,7 (73,0 / 27,4 / 10,9 / 8,4)
- 2025: 114,9 (73,4 / 33,0 / 0,9 / 7,6)
- -4,0%

Full year
- 2024: 261,9 (164,7 / 60,9 / 16,0 / 20,2)

RTM
- 2024/25: 257,0 (165,1 / 66,5 / 6,0 / 19,4)

Positive EBITDA momentum continues

EBITDA development

MSEK

■ EBITDA

| Second quarter (Apr-Jun) | Year to date (Jan-Jun) | Full year | RTM |

Second quarter (Apr-Jun)

- 2024: 1.2
- 2025: 4.4
- **+3.2**

Year to date (Jan-Jun)

- 2024: -0.3
- 2025: 13.8
- **+14.1**

Full year

- 2024: 18.0

RTM

- 2024/25: 32.1

The new Bactiguard

The **premier partner** for leading MedTech companies

Strategic focus

License partnerships ▶ **Advance current and develop new partnerships**

R&D Medical Regulatory ▶ **Continue to invest in key knowledge areas**

Wound Management portfolio ▶ **Grow profitably and expand into new markets**

Targets by year-end 2030

>10 application areas in either **exclusivity** or **license partnership**

>200 MSEK EBITDA

>600 MSEK Revenues

> *The most promising aspect of healthcare going forward is prevention, period.*

Doctor Richard Kuntz
BACTIGUARD BOARD MEMBER